Psychopharmacological Interventions

Seema M. Thekdi; María Elisa Irarráazaval; Laura B. Dunn

doi:10.1002/9781119941101.ch9

Psychopharmacological Interventions

Seema M. Thekdi, María Elisa Irarráazaval, Laura B. Dunn

Psychiatry

Research output: Chapter in Book/Report/Conference proceeding › Chapter

7 Scopus citations

Original language	English (US)
Title of host publication	Clinical Psycho-Oncology
Subtitle of host publication	An International Perspective
Publisher	John Wiley and Sons
Pages	109-126
Number of pages	18
ISBN (Print)	9780470974322
DOIs	https://doi.org/10.1002/9781119941101.ch9
State	Published - May 30 2012

Keywords

Antidepressant use in psycho-oncology settings
Antipsychotics in psychiatric, and nonpsychiatric symptoms
Anxiolytics and hypnotics, use in oncology settings
Choice of medication, dictated by side-effect profiles
Pharmacological issues in antidepressant use
Pharmacological, monitoring treatment for cancer patients
Psychopharmacological interventions
Psychotropics, in managing emotional distress, cancer symptoms
Recommended screening, monitoring, and caution
Side-effects and safety monitoring, and EPS

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781119941101.ch9

Cite this

@inbook{76ddd34f67b54b3f81361afbc6cfd516,

title = "Psychopharmacological Interventions",

keywords = "Antidepressant use in psycho-oncology settings, Antipsychotics in psychiatric, and nonpsychiatric symptoms, Anxiolytics and hypnotics, use in oncology settings, Choice of medication, dictated by side-effect profiles, Pharmacological issues in antidepressant use, Pharmacological, monitoring treatment for cancer patients, Psychopharmacological interventions, Psychotropics, in managing emotional distress, cancer symptoms, Recommended screening, monitoring, and caution, Side-effects and safety monitoring, and EPS",

author = "Thekdi, {Seema M.} and Irarr{\'a}azaval, {Mar{\'i}a Elisa} and Dunn, {Laura B.}",

note = "Funding Information: Dr. Thomas Spencer receives research support from, is a speaker for, or is on the Advisory Board of the following sources: Shire, Eli Lilly and Company, GlaxoSmithKline, Ortho-McNeil, Inc., Novartis, New River Pharmaceuticals, Cephalon, Pfizer, and the National Institute of Mental Health (NIMH). Dr. Joseph Biederman is currently receiving research support from the following sources: Bristol-Myers Squibb, Eli Lilly and Company, Janssen, L.P., Ortho-McNeil, Inc., Otsuka, Shire, NIMH, and the National Institute of Child Health and Human Development Dr. Joseph Biederman is currently a consultant/advisory board member for the following pharmaceutical companies: Janssen, L.P., Ortho-McNeil, Inc., Novartis, and Shire. Dr. Joseph Biederman is currently a speaker for the following speaker's bureaus: Janssen, Ortho-McNeil, Inc., Novartis, Shire, and UCB Pharma, Inc. In previous years, Dr. Joseph Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Company, Esai, Forest, GlaxoSmithKline, Gliatech Inc., NARSAD, New River Behavioral HealthCare, the National Institute on Drug Abuse, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, The Stanley Foundation, and Wyeth. ",

year = "2012",

month = may,

day = "30",

doi = "10.1002/9781119941101.ch9",

language = "English (US)",

isbn = "9780470974322",

pages = "109--126",

booktitle = "Clinical Psycho-Oncology",

publisher = "John Wiley and Sons",

}

TY - CHAP

T1 - Psychopharmacological Interventions

AU - Thekdi, Seema M.

AU - Irarráazaval, María Elisa

AU - Dunn, Laura B.

N1 - Funding Information: Dr. Thomas Spencer receives research support from, is a speaker for, or is on the Advisory Board of the following sources: Shire, Eli Lilly and Company, GlaxoSmithKline, Ortho-McNeil, Inc., Novartis, New River Pharmaceuticals, Cephalon, Pfizer, and the National Institute of Mental Health (NIMH). Dr. Joseph Biederman is currently receiving research support from the following sources: Bristol-Myers Squibb, Eli Lilly and Company, Janssen, L.P., Ortho-McNeil, Inc., Otsuka, Shire, NIMH, and the National Institute of Child Health and Human Development Dr. Joseph Biederman is currently a consultant/advisory board member for the following pharmaceutical companies: Janssen, L.P., Ortho-McNeil, Inc., Novartis, and Shire. Dr. Joseph Biederman is currently a speaker for the following speaker's bureaus: Janssen, Ortho-McNeil, Inc., Novartis, Shire, and UCB Pharma, Inc. In previous years, Dr. Joseph Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Company, Esai, Forest, GlaxoSmithKline, Gliatech Inc., NARSAD, New River Behavioral HealthCare, the National Institute on Drug Abuse, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, The Stanley Foundation, and Wyeth.

PY - 2012/5/30

Y1 - 2012/5/30

KW - Antidepressant use in psycho-oncology settings

KW - Antipsychotics in psychiatric, and nonpsychiatric symptoms

KW - Anxiolytics and hypnotics, use in oncology settings

KW - Choice of medication, dictated by side-effect profiles

KW - Pharmacological issues in antidepressant use

KW - Pharmacological, monitoring treatment for cancer patients

KW - Psychopharmacological interventions

KW - Psychotropics, in managing emotional distress, cancer symptoms

KW - Recommended screening, monitoring, and caution

KW - Side-effects and safety monitoring, and EPS

UR - http://www.scopus.com/inward/record.url?scp=84885387107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885387107&partnerID=8YFLogxK

U2 - 10.1002/9781119941101.ch9

DO - 10.1002/9781119941101.ch9

M3 - Chapter

AN - SCOPUS:84885387107

SN - 9780470974322

SP - 109

EP - 126

BT - Clinical Psycho-Oncology

PB - John Wiley and Sons

ER -

Psychopharmacological Interventions

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this